PARIS--(BUSINESS WIRE)--Gecko Biomedical, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, has announced it will change the company name to TISSIUM as part of an overall rebranding of the company. The new name more accurately reflects the company’s mission to develop novel solutions for tissue reconstruction for multiple clinical indications, by leveraging its research, development and commercialization capabilities.
TISSIUM has taken a modular approach to product development, developing a technology platform comprised of proprietary polymers, activation technologies, and delivery devices. This modular approach has enabled TISSIUM to innovate in different therapeutic areas, and leverage the knowledge gained from the development process.
The company has robust product development and manufacturing capabilities, and is able to bring new products to market independently, or in partnership with other industry players.
Christophe Bancel, CEO of TISSIUM, said: “The announcement of our rebranding to TISSIUM is an exciting milestone in the company’s development. When the co-founders started the company in 2013, we had an idea that the technology that we would offer to the medical community would be the start of innovation in a space that hadn’t seen significant changes in many years. Now, we feel we have an opportunity to offer a full platform of biomorphic programmable polymers to fundamentally change the way the industry thinks about tissue reconstruction, and it’s important that the brand reflect our intent.
The company’s corporate website has also been relaunched as part of this rebranding effort—please visit www.TISSIUM.com to learn more about TISSIUM.
TISSIUM is a privately-owned life sciences company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.
The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.
The Company’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com and @TISSIUMtech.